Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve to consider and approve the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek has informed BSE that its Board of Directors will meet on November 14, 2025 to consider and approve several items. The key business item is the Un-Audited Financial Results (Standalone & Consolidated) along with the Limited Review Report for the quarter and half year ended September 30, 2025 (Q2 FY26 / H1 FY26). The Board will also approve the Notice of the 35th Annual General Meeting for FY 2024-25, the Directors' Report, and fix the record/book closure dates and e-voting timeline. On the governance side, the Board will consider re-appointing Dr. K. Koteswara Rao as Chairman & Managing Director for one more year, and re-appointing three Independent Directors (Mrs. Sujana Kadiam, Mr. Santhosh Kumar, and Mrs. Swetha Marri) for a second 5-year term each, subject to shareholder approval. The trading window for insiders is already closed from October 1, 2025 until 48 hours after the Q2 results are made public.
This is a routine compliance intimation with no immediate price impact, but investors should watch the November 14 meeting for the Q2 FY26 results, which will be the next material data point for the stock. The re-appointment of the MD and three Independent Directors signals continuity in leadership and board composition.